Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.65 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL638359 | 0.97 | FOLH1 (0.62) | FOLH1GRM3NAALAD2 | |
| SCHEMBL108166 | 0.86 | FOLH1 (0.76) | FOLH1GRM3NAALAD2KDM4ATET2 | |
| SCHEMBL13726298 | 0.83 | FOLH1 (0.73) | FOLH1GRM3NAALAD2KDM4ATET2 | |
| SCHEMBL27996973 | 0.83 | FOLH1 (0.73) | FOLH1GRM3NAALAD2KDM4ATET2 | |
| SCHEMBL29060942 | 0.83 | FOLH1 (0.73) | FOLH1GRM3NAALAD2KDM4ATET2 | |
| SCHEMBL24533833 | 0.83 | FOLH1 (0.53) | FOLH1 | |
| SCHEMBL928641 | 0.82 | FOLH1 (0.64) | FOLH1GRM3NAALAD2 | |
| SCHEMBL15679634 | 0.80 | FOLH1 (0.48) | FOLH1GRM3NAALAD2KDM4ATET2 | |
| SCHEMBL28555785 | 0.80 | FOLH1 (0.43) | FOLH1GRM3NAALAD2 | |
| SCHEMBL27739702 | 0.80 | ALOX15 (0.54) | FOLH1GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250012780-A1 | Application of Organic Acids in Urine for Health Management | OU YUNG CHUN (TW) | 2025-01-09 | — | — | US | claimed |
| CN-119269659-A | Application of urine organic acid in health management | 欧湧淳 | 2025-01-07 | — | — | CN | claimed |
| CN-117158916-B | Vascular intervention medical device, vascular intervention medical system and application of vascular intervention medical device | 柔脉医疗(深圳)有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-115073615-B | Construction method of artificial cell-like device capable of improving catalytic efficiency of cell factory | 大连理工大学 | 2024-08-27 | — | — | CN | claimed |
| CN-113930348-B | Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof | 河北维达康生物科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117723644-A | Method for detecting water-soluble vitamins, hormones, nucleosides, organic acids and amino acids in biological sample | 南京品生医学检验实验室有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117204827-A | Vascular intervention diagnosis and treatment device, system and application thereof | 柔脉医疗(深圳)有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-117158916-A | Vascular intervention medical device, vascular intervention medical system and application of vascular intervention medical device | 柔脉医疗(深圳)有限公司 | 2023-12-05 | — | — | CN | claimed |
| US-20230178243-A1 | PREDICTING A RECOMMENDED THERAPY FROM GUT COMPOSITIONAL DATA | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| CN-115505605-B | Production method of ursolic acid | 北京理工大学 | 2023-02-24 | — | — | CN | claimed |
| CN-108627647-B | Detection and quantification method of post-translational modification proteomics | 四川大学 | 2020-06-19 | — | — | CN | claimed |
| CN-105765383-A | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | 唾液科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| US-RE40837-E1 | Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2009-07-07 | — | — | US | claimed |
| US-20080009449-A1 | Lignan complex derived from flax seed used for treatment of hypercholesterolemic atherosclerosis | SASKATCHEWAN, UNIVERSITY OF (CA) | 2008-01-10 | — | — | US | claimed |
| US-7109206-B2 | Methods and compositions for the rapid and enduring relief of inadequate myocardial function | HEART CARE PARTNERS (US) | 2006-09-19 | — | — | US | claimed |
| US-6673773-B2 | ADMINISTERING COMPLEX HAVING PURITY OF AT LEAST 95% DERIVED FROM FLAXSEED AND CONTAINING SECOISOLARICIRESINOL DIGLUCOSIDE, CINNAMIC ACID GLUCOSIDES AND HYDROXYMETHYL GLUTARIC ACID | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INCORPORATED (CA) | 2004-01-06 | — | — | US | claimed |
| US-20030212007-A1 | LIGNAN COMPLEX DERIVED FROM FLAXSEED AS HYPERCHOLESTEROLEMIC AND ANTI-ATHEROSCLEROTIC AGENT | UNIVERSITY OF SASKATCHEWAN (CA) | 2003-11-13 | — | — | US | claimed |
| EP-1192167-B1 | A COMPLEX CONTAINING LIGNAN, PHENOLIC AND ALIPHATIC SUBSTANCES FROM FLAX AND PROCESS FOR PREPARING | CA MINISTER AGRICULTURE & FOOD (CA) | 2003-04-09 | — | — | EP | claimed |
| US-20020016312-A1 | Methods and compositions for the rapid and enduring relief of inadequate myocardial function | HEART CARE PARTNERS | 2002-02-07 | — | — | US | claimed |
| US-6159993-A | Methods and compositions for the rapid and enduring relief of inadequate myocardial function | HEART CARE PARTNERS (US) | 2000-12-12 | — | — | US | claimed |